Sibyl Anderson - Concepedia

Author

Sibyl Anderson

Also Known As

S Anderson, S E Anderson, S. ANDERSON, S. Anderson, S.E. ANDERSON, Sean Anderson, Sean P. Anderson, Sibyl Anderson, Sibyl E. Anderson

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Bayer (United States)Institut Gustave Roussy Cleveland Clinic Massachusetts General Hospital

About

Sibyl Anderson is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	299
2	Immunology	2	2	77
3	Obstetrics	2	2	104
4	Health Sciences	1	1	16
5	Gastroenterology	1	1	16

Sibyl Anderson

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Bernard Escudier, Tim Eisen, Walter M. Stadler, Journal of Clinical Oncology	2009	1.1K
Phase II Study of Doxorubicin and Bevacizumab for Patients With Metastatic Soft-Tissue Sarcomas David R. D’Adamo, Sibyl Anderson, Karen Albritton, Journal of Clinical Oncology	2005	252
Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma Mario M. Leitão, Robert A. Soslow, Daisuke Nonaka, Cancer	2004	161
Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial Tim Eisen, Stéphane Oudard, Cezary Szczylik, JNCI Journal of the National Cancer Institute	2008	136
Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40 Jakob Dupont, Meena K. Tanwar, Howard T. Thaler, Journal of Clinical Oncology	2004	136
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Ghassan K. Abou‐Alfa, Dino Amadori, Armando Santoro, PubMed	2011	97
Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET Thomas E. Hutson, Joaquim Bellmunt, Camillo Porta, European Journal of Cancer UrologyGenitourinary CancerMedicineLong-term SafetyCancer Treatment	2010	77
Combined modality chemoradiation in elderly oesophageal cancer patients Sibyl Anderson, Bruce D. Minsky, Manjit S. Bains, British Journal of Cancer	2007	71
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer Erika Hamilton, Michelino De Laurentiis, Hiroji Iwata, Future Oncology	2024	70
Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study Mika A. Sovak, Jakob Dupont, Martee L. Hensley, International Journal of Gynecological Cancer	2006	63

Page 1